NG‐Nitro‐L‐arginine methyl ester: a muscarinic receptor antagonist?

Publisher Website
Google Scholar
Abstract
Summary— The effect of the nitric oxide synthase inhibitor NG-Nitro-L-arginine methyl ester (L-NAME) towards muscarinic receptors was studied in vitro and in vivo. L-NAME displaced the antimuscarinic ligand [3H]quinuclidinyl benzilate (3H]QNB) from its specific binding sites in rat cerebral cortex and cerebellum homogenates with a more than 10,000 fold lower affinity than atropine, pirenzepine and AFDX 116. Data for L-NAME binding were best fit according to a two-site model (Kd 7.2 nM and 3,000 nM) in the rat cerebellum, whereas in rat cortex a one-site model (Kd 1670 nM) was superior. In anesthetized rats and rabbits L-NAME (7.5–185 μmol/kg) attenuated a hypotensive response to Acetyl β-methyl-choline (Ac β-Me Ch)(6.25 nmol/kg) in a dose related fashion, but this effect was negligible as compared to that of atropine (8.8 and 17.7 nmol/kg). Furthermore, the effect of L-NAME was not specifically antimuscarinic since its attenuating effect against ATP- or histamine-induced responses was not statistically different from that of Ac β-Me Ch. A vagus stimulation induced bradycardia was entirely uninfluenced by L-NAME (37 μmol/kg). In isolated bladder experiments (rabbit) we demonstrated a complete lack of efficacy of L-NAME against Ac β-Me Ch induced contractions. In the pithed rat preparation L-NAME was ineffective against the McN-A-343 induced pressor responses. In summary, we demonstrated that the nitric oxide synthase inhibitor L-NAME shows very weak affinity at M1- and M2-receptors in the rat brain in vitro, but appears to have no significant antimuscarinic properties against M1-, M2- and M3-receptor mediated effects in rats and rabbits in vivo.